Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA-UCART in Relapsed or Refractory Multiple Myeloma
NCT03752541Phase 1Suspended
- Sponsor
- BRL Medicine Inc.
- Start
- Nov 2019
- Primary completion
- Mar 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA-UCART in multiple myeloma (MM), sponsored by BRL Medicine Inc. Primary endpoint: Objective Response Rate at 90 days. Started Nov 2019; status: suspended.
02
Drugs
BCMA-UCART
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03752541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03752541.